Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Pfizer Inc.
Current Parent Company: Pfizer
Penalty: $345,000,000
Year: 2021
Date: November 17, 2021
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Pfizer agreed to pay $345 million to resolve multi-district litigation alleging it colluded with Mylan to block generic versions of EpiPen, used to treat allergic reaction emergencies.
Level of Government: federal
Action Type: private litigation
Court: District of Kansas
Civil or Criminal Case: civil
Case ID: 2:17md2785
Case Name: In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices And Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: New York
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.